Skip to main content

Table 3 Comparison between dual PDE5i therapy group and historical control

From: Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study

 

Dual PDE5i group (N = 7)

Historical control (N = 10)

P value

Age (years)

39.9 ± 12.3

33.0 ± 12.1

0.271

Number of Female

7 (100%)

10 (100%)

N/A

Follow-up period (months)

9.6 ± 4.0

10.7 ± 1.8

0.438

mPAP (mmHg)

47.9 ± 9.7

46.2 ± 7.8

0.700

ΔmPAP at follow-up (mmHg)

−6.1 ± 3.6

0.7 ± 3.3

0.001

PVR (WU)

9.3 ± 2.7

10.9 ± 5.0

0.458

ΔPVR at follow-up (WU)

−2.6 ± 2.1

1.5 ± 2.2

0.001

CI (L/min/m2)

2.8 ± 0.9

2.8 ± 1.0

0.983

ΔCI at follow-up (L/min/m2)

0.3 ± 0.3

−0.4 ± 0.6

0.007

  1. mPAP: mean pulmonary artery pressure, PVR: pulmonary vascular resistance, WU: Wood’s units, CI: cardiac index.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us